WYETH-AYERST ESI-PHARMA TAKING ORDERS FOR FIRST ORAL GENERIC PRODUCT,
WYETH-AYERST ESI-PHARMA TAKING ORDERS FOR FIRST ORAL GENERIC PRODUCT, the progestin Cycrin, the company announced May 10. "The changing pharmaceutical environment in these cost conscious times demands that Wyeth-Ayerst broaden its product line and its appeal to large purchasers," the American Home Products subsidiary said, explaining its decision to re-enter the oral generic drug field. Cycrin (medroxyprogesterone acetate) is available in 2.5 mg, 5 mg, and 10 mg strengths. Cycrin is bioequivalent to Upjohn's Provera, which is indicated for amenorrhea (menopause) and abnormal uterine bleeding. Wyeth-Ayerst sells generic versions of injectable drugs through its Elkins Sinn subsidiary. The company briefly entered the oral generic drug business when it bought Quantum Pharmics in 1986. However, the generics firm was dissolved following FDA's discovery of fraudulent information in submissions. Wyeth's move follows similar actions by a number of major pharmaceutical companies. Merck announced in April that its West Point Pharma subsidiary plans to introduce 10 generic versions of off-patent Merck brands ("The Pink Sheet" April 19, T&G-12). Warner-Lambert, Zeneca (formerly ICI) and Marion Merrell Dow are manufacturing generic versions of their top-selling brandname drugs. Other firms, including Syntex and Upjohn, have disclosed plans to do the same. The rapid introduction of the progestin Cycrin may allow Wyeth-Ayerst managers to familiarize the trade with the combined use of Premarin conjugated estrogens and a cyclic progestin for post menopausal women. The company said it will file an NDA for its estrogen/progestin combination product Premarin MPA in the next few months. A study published in The New England Journal of Medicine, shows that Premarin and progestin in combination have an equal or superior effect on cardiovascular risk compared to conjugated estrogens alone in postmenopausal women ("The Pink Sheet" April 19, T&G-7). Progestin is added to hormone therapy to reduce the risk of uterine and breast cancer associated with estrogens in women who have not undergone hysterectomies. Wyeth-Ayerst said that generics manufactured by ESI-Pharma will be represented to the trade and managed care groups by Wyeth- Ayerst trade and government relations managers and managed care corporate account managers.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth